The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TNYA | -69.09% | N/A | N/A | -91% |
| S&P | +12.83% | +86.37% | +13.24% | +55% |
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. It operates through its product platforms: gene therapy, cellular regeneration, and precision medicine. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Olson in August 2016 and is headquartered in South San Francisco, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$1,864.00K | 11.3% |
| Market Cap | $264.02M | 73.4% |
| Market Cap / Employee | $2.72M | 0.0% |
| Employees | 97 | -30.7% |
| Net Income | -$20,275.00K | 20.9% |
| EBITDA | -$19,072.00K | 22.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $56.31M | 584.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.60M | -25.4% |
| Short Term Debt | $2.93M | -2.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -76.77% | -6.6% |
| Return On Invested Capital | -43.50% | -33.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$15,625.00K | 22.0% |
| Operating Free Cash Flow | -$15,599.00K | 21.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.01 | 0.53 | 0.83 | 2.64 | 132.84% |
| Price to Tangible Book Value | 1.01 | 0.53 | 0.83 | 2.64 | 132.82% |
| Enterprise Value to EBITDA | -3.36 | 0.51 | -1.82 | -11.53 | 179.85% |
| Return on Equity | -95.7% | -76.2% | -85.2% | -96.4% | 14.14% |
| Total Debt | $13.61M | $12.91M | $12.21M | $11.53M | -20.71% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
